A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2019
Price : $35 *
At a glance
- Drugs CLL 442 (Primary)
- Indications Carcinoma; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Dec 2018 Status changed from recruiting to completed.
- 21 Nov 2018 Planned End Date changed from 2 Nov 2018 to 16 Aug 2021.
- 21 Nov 2018 Planned primary completion date changed from 2 Nov 2018 to 16 Aug 2021.